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Abstract: Genetic engineering of plants has turned out to be an attractive approach to produce
various secondary metabolites. Here, we attempted to produce kynurenine, a health-promoting
metabolite, in plants of Nicotiana tabacum (tobacco) transformed by Agrobacterium tumefaciens with
the gene, coding for human indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme responsible for the
kynurenine production because of tryptophan degradation. The presence of IDO1 gene in transgenic
plants was confirmed by PCR, but the protein failed to be detected. To confer higher stability to the
heterologous human IDO1 protein and to provide a more sensitive method to detect the protein of
interest, we cloned a gene construct coding for IDO1-GFP. Analysis of transiently transfected tobacco
protoplasts demonstrated that the IDO1-GFP gene led to the expression of a detectable protein and
to the production of kynurenine in the protoplast medium. Interestingly, the intracellular localisation
of human IDO1 in plant cells is similar to that found in mammal cells, mainly in cytosol, but in early
endosomes as well. To the best of our knowledge, this is the first report on the expression of human
IDO1 enzyme capable of secreting kynurenines in plant cells.
Keywords: protoplasts; kynurenine; genetic transformation
1. Introduction
The production of recombinant proteins in plants dates back to the end of 1980s [1],
and since then many recombinant proteins have been produced in plants for different
uses, spanning from biomedical applications to industrial production [2,3]. Plant platforms
employing different expression systems have been developed, with the main distinction
between stable transformation, where transgenes can be integrated either in the nuclear
DNA or in the plastid DNA [4,5], and transient expression [6]. Foreign genes have been
transferred into the plants by Agrobacterium tumefaciens-mediated transformation meth-
ods [7,8] or other delivery systems including particle bombardment, PEG-mediated DNA
uptake in wall-free protoplasts [9], and nanomaterial-based delivery devices [10]. However,
plant expression procedures share some common characteristics such as the production of
favourable post-translational modifications and the absence of contaminating endotoxins
and animal viruses, which are serious issues in bacterial and eukaryotic expression sys-
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tems. Several reports have shown the successful expression of bioactive human proteins in
plants [11–13].
Indoleamine 2,3-dioxygenase 1 (IDO1) represents one of the most interesting proteins
which links an ancient metabolic pathway with immune regulation. IDO1 is a heme-
containing enzyme that catalyses the oxidative cleavage of the indole ring in L-tryptophan,
regulating the catabolism of this essential amino acid at an initial, rate-limiting level in
a specific pathway. This activity leads to the kynurenine production, which is the up-
stream metabolite along the so-called kynurenine pathway [14]. IDO1 is widely recognised
as an authentic immune regulator capable of fine-tuning immune responses not only
in pregnancy [15] but also in several pathological conditions, such as autoimmune dis-
eases [16,17], chronic inflammation [18], transplantation [19], and neoplasia [20]. IDO1
immunoregulatory effects are mainly mediated by dendritic cells (DCs), the most potent
antigen-presenting cells in the mammal immune system that, upon IDO1 upregulation,
acquire tolerogenic functions. In fact, through its enzymatic activity, IDO1 generates both
tryptophan deprivation in local tissue microenvironments and the formation of bioactive
metabolites collectively called kynurenines. In particular, several kynurenines reinforce the
immunoregulatory circuit in mammals by acting as a ligand of aryl hydrocarbon receptor
(AhR) in both T cells and DCs [21]. As a result, IDO1-expressing DCs mediate multiple ef-
fects on T lymphocytes, including inhibition of proliferation, apoptosis, and differentiation
towards a regulatory phenotype [22]. Moreover, apart from being a cytoplasmic enzyme,
IDO1 also acts as a signal-transducing molecule by binding tyrosine phosphatases in its
immunoreceptor tyrosine-based inhibitory motif (ITIM) domains [23] and anchoring to
the early endosomes. This localisation is a result of the IDO1 interaction with activated
class IA PI3K subunits [24]. Thus, the IDO1 ability to restrain inflammation depends on
two distinct functions of the IDO1 protein: one is enzymatic (tryptophan degradation to
kynurenine) while the other is independent from its enzymatic function.
Potential clinical applications of kynurenine are growing. Kynurenine is required for
the production of several metabolites, being the first metabolite in the kynurenine pathway,
which leads to the final biosynthesis of nicotinamide adenine dinucleotide (NAD+). Among
these metabolites, kynurenic acid and xanthurenic acid, as well as their analogues, have
neuroprotective activities, suggesting that they may find use in drug development for
neurological diseases [25–28]. Moreover, NAD+ is a coenzyme with a pivotal role in a vast
number of biochemical processes, as well as in several redox reactions, and it is vital to
mitochondrial function [29].
In this study, considering the only options for kynurenine production as chemical
synthesis or extraction from human tissues, we expressed human IDO1 in plant cells in
order to investigate the possibility to obtain an alternative production platform for both
IDO1 protein and biologic kynurenine.
2. Results
2.1. Cloning of IDO1 cDNA in a Plant Expression Vector and Attempted Stably Expression in
Tobacco Plants
A comparison of the human IDO1 amino acid sequence and the plant protein databases
was performed. We found some similarity within plants and green algae only at a low
percentage with an identity average of around 30%. Since alignment errors can appear
when the sequence identity drops below 35% [30], these sequence homologies seemed to
be too low to confirm the presence of IDO1 in the Plantae kingdom. Moreover, most of
these proteins were reported to have an unknown function and, in the few cases of being
identified as indoleamine 2,3-dioxygenase enzymes, the evidence supporting the existence
was inferred only by homology.
Therefore, to express IDO1 in plants, we cloned the human IDO1 cDNA into plant
expression vector pGreenII, obtaining pGreenII.IDO1. A schematic diagram of the vector
assembly is shown in Figure 1A. Then, we transformed tobacco (N. tabacum cv. Petit
Havana) plants with A. tumefaciens harbouring the pGreenII.IDO1 vector to obtain plants
stably expressing human IDO1. Selection with kanamycin allowed for the regeneration
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of transformed plants (T0), as shown in Figure 1B (left panel). Regenerated shoots were
successively separated from chlorotic leaf discs and placed in fresh selective medium to
stimulate further growth and roots formation (Figure 1B, central panel). As expected, wild-
type non-transformed plants failed to regenerate when placed in freshly selective medium
(Figure 1B, right panel). Total DNA was isolated from leaves of selected regenerated T0
plants and examined by PCR (Figure 1C). Only transformed explants showed an amplified
fragment of about 500 bp, confirming the presence of the IDO1 gene cassette in their
genome. Few T0 events unable to amplify were considered as regeneration escapes. In
total, 10 PCR-positive plants were chosen, transplanted to pots in controlled greenhouse
conditions, and reared to flower for seed production. Seeds were germinated on kanamycin
selective medium and for several plants (T1 events). IDO1 gene presence was confirmed by
PCR analysis (Figure 1D). However, even if IDO1 mRNA was detected by RT-PCR in leaves
(Figure 1E), IDO1 protein was undetectable by Western blotting in total proteins extracted
from leaves and roots of transformed plants, suggesting a protein stability problem.














Figure 1. Attempt of human IDO1 protein stable expression in tobacco plants. (A) Schematic dia-
gram of pGreen.IDO1 vector cloning. Abbreviations: 35S P, 35S promoter sequence; 35S T, 35S ter-
Figure 1. Cont.
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Figure 1. Attempt of human IDO1 protein stable expression in tobacco plants. (A) Schematic diagram
of pGreen.IDO1 vector cloning. Abbreviations: 35S P, 35S promoter sequence; 35S T, 35S terminator
sequence; NOS P and NOS T, A. tumefaciens nopaline synthase (nos) promoter and terminator se-
quence, respectively; LB, left border; RB, right border; KanR, gene encoding for kanamycin resistance.
The annealing positions of primers 35S1, 35S2, and IDO1 are shown. (B) Transgenic tobacco plant
selection and regeneration on MS medium with kanamycin after A. tumefaciens co-cultivation. Only
transformed cells were able to regenerate on selective medium (left panel). Regenerated shoots were
separated from chlorotic leaf discs and sub-cultured to allow growth and rooting (central panel).
No regeneration occurred when WT leaf discs were placed on antibiotic selective medium (right
panel). (C) PCR on some tobacco primary regeneration events (T0) with primers 35S1/IDO1. The
amplification signal was detectable only in transformed plants (2–5), whereas plants 1 and 6 were
probably regeneration escapes. (D) One T1 plant deriving from seeds of each of the 10 primary
transformants (T1n; n = 1–10) were analysed by PCR with primers 35S2/IDO1, confirming the presence
of the IDO1 transgene. There were two empty lanes between the lanes WT and T11. (E) Different
transformed plants (2−5) were analysed for the presence of IDO1 mRNA by RT-PCR. Actin was
amplified as a reference gene for the RT-PCR experiment. (C–E) WT: wild type plant; (C,D) C+:
pGreen.IDO1 vector; C-: no DNA.
2.2. Human IDO1-GFP Can Be Transiently Expressed in Tobacco Protoplasts
The lack of human IDO1 expression in plants could possibly be attributed to protein
instability. Therefore, a second cloning strategy was carried out by fusing IDO1 sequence
to the GFP tag, aiming to obtain a more stable fusion protein, as frequently observed in
fusion technology [31]. For this purpose and for obtaining a tag useful as both a protein
detector and a possible purification system, we assembled the gene construct coding for
IDO1-GFP under the same constitutive promoter previously used in pGreenII.IDO1, the
35S promoter (Figure 2A), and we transiently transfected tobacco protoplasts with the new
vector pV.IDO1-GFP. By means of Western blotting with two different antibodies detecting
IDO1 protein and the GFP tag, respectively, we revealed the expression of a 69 kDa protein,
matching the size of IDO1-GFP, in plants transfected with pV.IDO1-GFP (Figure 2B). In
order to avoid possibile impact of tryptophan depletion, due to the catalytic activity of
IDO1, on cell vitality and protein expression, we added an extra amount of tryptophan to
the protoplast medium. The additional tryptophan did not change IDO1 protein expression
in protoplasts, as shown in (Figure 2B). As a result, IDO1 can be expressed in vitro as a
GFP-fused protein in transiently transformed protoplasts.
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rubisco large subunit (rbcL) was used to verify protein normalisation. After transformation, half of 
the protoplasts were incubated with tryptophan 100 µM (Trp), and the other half remained un-
treated (Untr). One representative immunoblot analysis of three is shown. 
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tryptophan into kynurenine. Therefore, we investigated if IDO1-GFP transiently 
expressed in protoplasts had enzymatic activity. For this purpose, we measured 
kynurenine concentration in K3 medium after a 24 h incubation of protoplasts in medium 
alone or with extra tryptophan added to enhance and detect the metabolic product (Figure 
3A). As a control, kynurenine was also measured in non-transformed protoplasts 
subjected to the same culture conditions. Human IDO1 expressed in protoplasts was 
found to be capable of producing kynurenine, but this effect was strictly related to the 
enzyme presence. In fact, the WT control protoplasts showed undetectable production of 
kynurenine in comparison with the IDO1-transfected cells, both in the presence and 
absence of an extra amount of tryptophan in the medium (Figure 3A). As an additional 
control, tobacco protoplasts were also transformed with the empty vector, and the 
Figure 2. IDO1-GFP expression in protoplasts. (A) Schematic diagram of pV.IDO1-GFP construct
cloning. Abbreviations are the same of Figure 1A. (B) Western blot analysis. IDO1 accumulation
was analysed in whole-cell lysates of protoplasts transfected (IDO1) or not (WT, wild type) with
pV.IDO1-GFP vector by using both an IDO1 and a GFP specific antibody. An antibody against rubisco
large subunit (rbcL) was used to verify protein normalisation. After transformation, half of the
protoplasts were incubated with tryptophan 100 µM (Trp), and the other half remained untreated
(Untr). One representative immunoblot analysis of three is shown.
2.3. Transiently Expressed IDO1-GFP Had Catalytic Activity and Similar Subcellular Localisation
of Mammal IDO1
In mammal cells, IDO1 catalyzes the conversion of the essential amino acid tryp-
tophan into kynurenine. Therefore, we investigated if IDO1-GFP transiently expressed
in protoplasts had enzy atic activity. For this purpose, we measured kynurenine con-
centration in K3 medium after a 24 h incubation of protoplasts in medium alone or with
extra tryptophan added to enhance and detect the metabolic product (Figure 3A). As a
control, re i e as also measured in non-transformed protoplasts subjected to the
same culture conditi s. Human IDO1 expressed in protoplasts was found to be capable of
producing kynurenine, but this effect was strictly related to the nzyme presence. In fact,
the WT control protoplasts showed undetectable pro uction of kynurenine in comparison
with the IDO1-transfected cells, both in the presence and absence of an extra amount of
tryptophan in he medium (Figure 3A). As an additional control, tobacco protoplasts were
also transformed ith the empty vector, and the kynurenine concentration measured in
their K3 medium resulted in being undetectable, similar to what we found in WT proto-
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plasts. Moreover, the addition of tryptophan to the medium allowed for the production of
a significantly higher level of kynurenine as compared to untreated IDO1-transfected cells.
Unexpectedly, the final (i.e., after the 24 h incubation) tryptophan level measured in the
medium with extra-added tryptophan (100 µM) was significantly higher in the presence of
transfected IDO1 cells than in the WT control (Figure 3B).
As recently demonstrated, in mammal cells, IDO1 is localised not only in the cytosol
but also in early endosomes [24]. To investigate the intracellular localisation of human
IDO1 in plant cells, we analyzed leaves of soil-grown tobacco plants transfected in vivo by
A. tumefaciens cultures with both pV.IDO1-GFP and red fluorescent protein (RFP)-tagged
organelle markers. Confocal analysis revealed that IDO1 was primarily found in a diffuse
pattern consistent with cytoplasmic localisation. However, a partial compartmentalisation
of IDO1 protein to prevacuolar compartments/multivesicular bodies (PVC/MVB) was
also observed when co-expressed with a PVC/MVB marker (TR2RFP-VSR2) (Figure 3C).
PVC/MVB are intermediate compartments mediating protein transport between trans-
Golgi network (TGN) and vacuole, holding overlapping functions with mammalian early
endosomes. Since plant organelles are not perinuclear as in mammalian cells, statistical
analysis of co-localisation events could be performed to evaluate the relevance of the
results. As seen in Figure 3C, Pearson’s correlation (rp) and Spearman correlation (rs)
resulted in coefficients of 0.43 and 0.2, respectively. Since perfect co-localisation would
result in statistical coefficients close to 1, our results confirmed the partial localisation of
IDO1 at PVC/MVB membrane when co-expressed with TR2RFP-VSR2 (Figure 3C). On
the contrary, IDO1 could not be found co-localising with other cell compartments of the
secretory pathway when co-expressed with markers of the late prevacuolar compartment
(RFP-Rha1, LPVC marker), Golgi apparatus (ST-RFP marker), or trans-Golgi network
(RFP-SYP61, TGN marker) (Figure 3D).
As a whole, on the basis of these data, we found that GFP-tagged IDO1 can be
transiently expressed in protoplasts in a catalytically active conformation and has a similar
intracellular localisation to that found in mammalian cells.










Figure 3. (A) Kynurenine (Kyn) and (B) tryptophan (Trp) concentrations were assessed in the me-
dium of transformed (IDO1) or untransformed (WT, wild type) protoplasts maintained for 24 h in 
culture in the presence (Trp) or absence (Untr) of tryptophan excess (100 µM). Concentrations be-
low the detection limit are indicated as not detectable (n.d.). In (A) and (B), data are means ± S.D. 
of three experiments, each performed in triplicate. Data were analysed by one-way ANOVA fol-
lowed by Bonferroni’s post hoc test. ** p < 0.01; **** p < 0.0001. (C, D) Confocal immunofluores-
cence microscopy images of Agrobacterium-infiltrated tobacco leaf cells coexpressing IDO1-GFP 
with various organelle markers carrying an RFP tag. The cells are shown in three-channel mode 
(green, red, and merge). Scale bar, 5 nm. (C) A partial compartmentalisation of IDO1 protein 
(green channel) to the prevacuolar compartments/multivesicular bodies (PVC/MVB) marker (red 
channel) was observed in the merged image. The statistical colocalisation between IDO1 and 
Figure 3. Cont.
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Figure 3. (A) Kynurenine (Kyn) a d (B) ryptophan (Trp) co centrations were assessed in the
medium of transformed (IDO1) or untransformed (WT, wild type) protoplasts maintained for 24 h in
culture in the presence (Trp) or absence (Untr) of tryptophan excess (100 µM). Concentrations below
the detection limit are indicated as not detectable (n.d.). In (A,B), data are means ± S.D. of three
experiments, each performed in triplicate. Data were analysed by one-way ANOVA followed by
Bonferroni’s post hoc test. ** p < 0.01; **** p < 0.0001. (C,D) Confocal immunofluorescence microscopy
images of Agrobacterium-infiltrated tobacco leaf cells coexpressing IDO1-GFP with various organelle
markers carrying an RFP tag. The cells are shown in three-channel mode (green, red, and merge).
Sc le bar, 5 n . (C) A partial compartmentalisation of IDO1 protein (green channel) to the prevacuolar
compartm nts/multivesicular bodies (PVC/MVB) mark r (red ch nel) was observed in the merged
image. The statistical colocalisation between IDO1 and PVC/MVB marker is shown, with Pearson’s
correlation coefficient (rp) of 0.43 and Spearman correlation coefficient (rs) of 0.2. (D) IDO1 did not
seem to colocalise with cell compartments of the secretory pathway such as the Golgi, the trans-Golgi
network (TGN), or the late prevacuolar compartment (LPVC).
3. Discussion
The production of biopharmaceuticals in plant has been named as “molecular farm-
ing” [32,33]. In particular, plants can be used to produce pharmaceutical proteins, such as
replacement human proteins, antibodies, and vaccine candidates [3]. Several recombinant
human proteins with therapeutic activity have been produced in plants, for example, the
enzyme alpha-mannosidase is produced in stably transformed plants for the replacement
therapy of the lysosomal storage disease alpha-mannosidosis. Another enzyme, named
glucocerebrosidase, is produced in plant cell suspension cultures and commercialised [13]
for Gaucher’s disease treatment. Furthermore, plant cell cultures represent interesting
options for an easy and scalable production of secondary metabolites, such as the anticancer
drug paclitaxel [34]. Thus, in addition to whole plants grown in greenhouse, plant in vitro
systems for generating metabolites and recombinant proteins are now considered an attrac-
tive alternative to classical technologies [35,36]. Although the efficiency of plant platforms
for biological components production is largely recognised, prokaryotic and mammalian
expression systems are still mainly used in biotechnological processes because, provided
with a strong regulatory framework, they guarantee robustness and economic sustainability
for the industrial platform [3]. Nevertheless, plant platforms might be attractive for the
production of certain biopharmaceuticals with favourable glycan configurations, as well as
for a rapid scale up process in the production of recombinant protein. Moreover, plants
certainly do not allow the growth of human pathogens [37,38].
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In the current report, a cloning strategy was set for the expression of a catalytically
active form of human IDO1 in plant cells, with the aim of exploring an alternative platform
for the kynurenine production. This molecule is an agonist of AhR, a crucial factor in
the immune response regulation that exerts its roles through different immunoregulatory
mechanisms. In fact, when activated, AhR is capable of inhibiting the production of several
proinflammatory cytokines and of controlling the generation of regulatory T (Treg) cells
and/or T helper 17 (Th17) cells in mouse models of autoimmune diseases [39]. The finding
of possible kynurenine participation in a positive feedback loop in AhR signalling paves
the way to a probable use of kynurenine as an immunoregulatory drug.
Plant organisms naturally produce all amino acids including tryptophan, which not
only result as an essential component of protein synthesis, but also serves as a precursor
for a wide range of indole-containing secondary metabolites that are important for plant
growth, such as auxin [40]. Therefore, the catalytic activity of recombinant human IDO1 in
transformed plants could be exploited to produce kynurenine in an organism normally
producing large quantities of its precursor. Apart from arylformamidase, plants do not
possess orthologous genes coding for enzymes involved in the kynurenine pathway [41].
Rice (Oryza sativa) seems to be an exception because genomic database searching has
revealed the presence of several biosynthetic genes encoding core enzymes in kynurenine
pathways, despite a lack of biochemical evidence [41]. In particular, the sequence of an
IDO1 gene (OsIDO) was identified, coding for a protein with a low identity (26%) and low
similarity (42%) to Mus musculus IDO1. However, the enzymatic activity of OsIDO had
not been demonstrated [42]. Hence, during our study, we generated a specific vector for
efficient transfection of human IDO1 gene in plants. Although the genetic transformation
had been effective and the transgene transcription did occur, transformed plants failed to
express IDO1 protein. A possible explanation could be the instability and/or the rapid
degradation of human IDO1 protein in a heterologous platform such as the plant cell.
Therefore, a different construct was cloned encoding for the fusion protein IDO1-GFP with
the aim of improving the protein stability. In order to rapidly test the expression of this
new gene construct, we transiently transfected protoplasts, plant cells with their cell wall
removed, and cultivated them in vitro in a liquid medium. Under these conditions, IDO1-
GFP fusion protein was expressed, accumulated in the protoplasts and, most importantly,
secreted kynurenine in the medium. Heterologous protein expression and kynurenine
production in protoplasts were also assessed in the presence of an excess of tryptophan in
order to compensate the depletion caused by the IDO1-metabolising activity that could
interfere with the plant cell development, as recently demonstrated. In fact, according
to He and colleagues [43], kynurenine is an alternative substrate that can competitively
inhibit the key enzymes involved in the conversion of tryptophan into indole-3-pyruvic
acid in one of the auxin biosynthesis pathways. They indicated the structural similarity
between kynurenine and tryptophan as the cause of kynurenine-mediated inhibition of
auxin biosynthesis in roots of Arabidopsis thaliana seedlings when grown in a medium
containing kynurenine. Interestingly, they found that the effect of kynurenine treatment
could be suppressed by the presence in the medium of high doses of tryptophan. In our
study, we observed that the extra tryptophan supplementation to the protoplast medium,
rather than affecting the catalytic activity of IDO1-GFP, increased fourfold the production
of kynurenine. These findings suggest that kynurenine production increases according to
the availability of the substrate tryptophan in the medium, and IDO1 activity promotes an
increased level of tryptophan in the medium by a still unidentified mechanism. The latter
aspect is not less important for a nutraceutical application. In fact, tryptophan for humans
is an essential amino acid necessary for the in vivo biosynthesis of proteins, as well as a
precursor of several bioactive compounds. It is widely used as a dietary supplement for
several perceived benefits, such as sleep and mood regulation [44], and it is reported to
mitigate the course of several chronic diseases, such as Chron’s disease [45]. Finally, in
plants, IDO1 keeps the same dual localisation recently found in mammalian cells [46]. In
fact, when expressed in vivo in tobacco leaves via Agrobacterium infiltration and observed
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by confocal microscopy, the majority of IDO1-GFP are found in the cytoplasm, with partial
colocalisation with the early endosomes.
In summary, this study demonstrates that in plant cells IDO1-GFP shares the same
enzymatic activity and subcellular distribution with native IDO1, paving the way to the
possible use of plants as bioreactors to produce kynurenine. To the best of our knowledge,
this is the first report on kynurenine production in plant cells by expressing human IDO1
protein. Further studies will be necessary to verify if a negative IDO1-mediated interference
with plant metabolism may occur during plant growth.
4. Materials and Methods
4.1. Construction of Plasmids for Plant Transformation
To stably express IDO1 in tobacco plants, we excised human IDO1 cDNA from plas-
mid pEZM02.IDO1 using EcoRI and NotI restriction enzymes. After excision, both 5′ and
3′ sticky ends were blunted by DNA polymerase I large (Klenow) fragment to allow non-
compatible ends joining. The result of digestion was separated on a 1% agarose gel and the
IDO1 band was isolated and purified using the T-Pro Gel/PCR DNA Purification kit (T-Pro
Biotechnology, New Taipei County, Taiwan). The plant vector pDHA [47] was linearised
with BamHI restriction enzyme, blunted as described above, dephosphorylated using calf
intestinal alkaline phosphatase (CIAP), and ligated to the IDO1 fragment to obtain the
pDHA.IDO1 intermediate vector, where IDO1 was under the control of the constitutive 35S
cauliflower mosaic virus (CMV) promoter and the 35S terminator suitable for plant expres-
sion. For the production of transgenic plants, we introduced the expression cassette excised
by EcoRI digestion from the pDHA.IDO1 plasmid into the pGreenII.0029 binary vector [7]
opened with the same restriction enzyme, obtaining pGreen.IDO1. This final plasmid was
sequenced to verify the correct sequence and orientation of the IDO1 expression cassette.
Strain GV3101 of A. tumefaciens was transformed by electroporation with the pGreenII.IDO1
vector and used to produce transgenic tobacco (N. tabacum cv. Petit Havana), as described
by Pompa and colleagues [48]. Briefly, tobacco plants were transformed by co-cultivation
with A. tumefaciens harbouring pGreenII.IDO1 on agar-solidified MS medium containing
1 mg/L of 6-benzylaminopurine (BA) and 0.1 mg/L of α-naphthaleneacetic acid (NAA)
hormones. After co-cultivation, the leaf discs were grown aseptically in Petri dishes at
25 ◦C under full light on the same medium supplemented with 500 mg/L of cefotaxime and
100 mg/L kanamycin to avoid Agrobacterium growth and to select transformed cells, respec-
tively. Shoots emerging from each explant were kept separated to guarantee regeneration
of independent transformants. After approximately 5–6 weeks, shoots were plated on MS
medium without hormones but still supplemented with antibiotics until new plants devel-
oped. Transformed plants (T0) were grown at 25 ◦C in 16 h of light in axenic culture in glass
jars without antibiotics and propagated every 5–6 weeks. After PCR results, 10 transgenic
plants (labelled with numbers from 1 to 10) were chosen and reared to flower to obtain
seeds. T1 seeds from self-fertilisation were harvested at maturity, seeded onto kanamycin
selective medium, and scored for resistance. After 21–28 days, resistant seeds started to
germinate. One T1 plant deriving from each of the 10 primary regenerants, T1n (n = 1–10),
was analysed by PCR to confirm the IDO1 gene presence. To fuse GFP in frame to IDO1 at
the C-terminal, we amplified IDO1 cDNA with PCR from pDHA.IDO1 with the forward
primer IDO1ClaI (GCAGACTACATCGATGGCACACGCTATGG) and the reverse primer
IDO1NheI (GGCCGCTAGCACCTTCCTTCAAAAG). The PCR fragment was digested by
ClaI and NheI restriction enzymes and inserted in the vector pJA1, derived from pAW7
after replacing the RFP with GFP [49]. The resulting vector (pUC.IDO1-GFP) contained
the 35S promoter and the IDO1 sequence in frame with a C-terminal GFP, followed by the
NOS terminator in a EcoRI-HindIII cassette. Since IDO1 coding sequence contained another
HindIII site (Figure 2A), the digestion of pUC.IDO1-GFP by EcoRI/HindIII generated two
fragments. Both fragments were cloned in the pV binary vector for plant transformation
and digested with EcoRI/HindIII in order to reconstitute the original IDO1-GFP. This recon-
stituted cassette was sequenced to confirm the integrity of IDO1 gene and the frame with
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GFP. The resulting vector pV.IDO1-GFP was used for tobacco protoplast transformation
and, after transformation into A. tumefaciens, for infiltration experiments.
4.2. Tobacco Protoplast Isolation
Protoplasts were isolated from transgenic plants as described by De Marchis et al. [50].
Briefly, to isolate mesophyll protoplasts, we wounded young fully expanded leaves from
tobacco plants grown under aseptic conditions with a scalpel and placed them in a Petri
dish with the abaxial side in contact with the 1× enzyme mix solution (in 1% Cellulase
Onozuka RS, 0.5% Macerozime R-10) dissolved in K3 medium (3.78 g Gamborg’s B-5
Basal Medium with Minimal Organics, 5.1 mM CaCl2·2H2O, 3.12 mM NH4NO3, 0.4 M
sucrose, 1.67 mM xylose, BA 1 mg/L, NAA 1 mg/L (pH 5.5)) for 16 h at 25 ◦C in the dark.
Protoplasts were recovered by resuspending macerated leaves in K3 medium, filtering
through a sterile 85 µm nylon mesh, and centrifuging for 20 min at 60× g with a swinging
bucket rotor. The floating green band, representing vital protoplast, was recovered and
washed twice with W5 solution (152 mM NaCl, 5 mM KCl, 125 mM CaCl2·2H2O, 5 mM
glucose). After testing viability and yield with fluorescein diacetate staining, we used
protoplasts for further analysis.
4.3. Tobacco Protoplast Transformation
After W5 removal by centrifuging for 10 min at 60× g, protoplasts were resuspended
at a concentration of 1 × 106 mL−1 with MaCa buffer (0.1% MES, 20 mM CaCl2, 0.5 M
mannitol (pH 5.6)), heated at 45 ◦C for 5 min, and mixed with 60 µg of plasmid DNA mL−1
of protoplast suspension. Protoplast transformation with polyethylene glycol (PEG) was
performed by adding an equal volume of a solution containing 40% (w/v) PEG 4000, 0.1 M
Ca(NO3)2, and 0.4 M mannitol (pH 8). After incubation at room temperature for 30 min,
transformed protoplasts were slowly diluted to 14 mL with W5 solution. Protoplasts
were pelleted at 60× g for 10 min at room temperature, resuspended in K3 medium to a
final density of 1 × 106 protoplasts mL−1, and incubated 2 h at 25 ◦C in the dark. Then,
tryptophan 100 µM was added to half of the samples, and all the protoplasts were incubated
for 24 h at 25 ◦C in the dark before subsequent analysis.
4.4. Plant Transformation by Agroinfiltration and Microscopy Analysis
Soil-grown N. tabacum cv. Petit Havana [51] leaves were infiltrated at OD 0.1 with A.
tumefaciens cultures containing the pV-IDO1-GFP alone or with either organelle marker such
as ST-RFP (Golgi marker), RFP-SYP61 (TGN marker), TR2RFP-VSR2 (PVC/MVB marker),
or RFP-Rha1 (LPVC marker), as described previously [52]. The infiltrated areas were
analysed 48h post-infiltration by confocal laser scanning microscopy. Confocal imaging
was performed using an inverted Zeiss LSM 700 laser scanning microscope. When GFP
fusions were imaged with RFP organelle markers, samples were excited with a diode
laser at the wavelength of 488 nm for GFP and 555 nm for RFP. Fluorescence was detected
with a 552 nm dichroic beam splitter and a 475 to 550 nm bandpass filter for GFP and a
560 to 700 nm bandpass filter for RFP. All dual-colour imaging was performed by line
switching to obtain adequate live bioimaging data that had not been distorted by organelle
motion. Statistical colocalisation between IDO1-GFP and TR2RFP-VSR2 was performed as
described in Gershlick et al. [53].
4.5. DNA Isolation and Analysis
Total DNA was isolated from wild type and transgenic tobacco leaves using the GenE-
lute™ Plant Genomic DNA Miniprep kit (Merck KGaA, Darmstadt, Germany). DNA PCR
amplification was carried out using the primer pairs forward 35S1 (5′-ACGTTCCAACCAC
GTCTTCAAAG-3′) and reverse IDO1 (5′-GCAAGACCTTACGGACATCT-3′) and forward
35S2 (5′-CATGGAGTCAAAGATTCAAA-3′) and reverse IDO1 for T0 and T1 plants, re-
spectively.
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4.6. RNA Extraction and RT-PCR Analysis
Total RNA was extracted from leaf tissues of transformed plants with the NucleoSpin®
RNA Plant kit (Macherey–Nagel, Düren, Germany). For the reverse-transcribed PCR
(RT-PCR) analysis, RNA was treated with DNase I (Qiagen, Venlo, The Netherlands) and
reverse-transcribed (2 µg) using oligo(dT)18 and the SuperScript III Reverse Transcrip-
tase (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer’s
instructions. The cDNA preparations were analysed by PCR using specific primers
for human IDO1 (forward, 5′- CTCCTGGACAATCAGTAAAGAGTACC-3′; reverse, 5′-
ACTTCTCAACTCTTTCTCGAAGCTGG-3′) and plant actin (forward, 5′- ATGGCGGATGG
GGAGGACATTCA-3′; reverse, 5′- CCTTTTGTTATCCACATCTGTTG-3′).
4.7. Protein Extraction from Protoplasts and Western Blotting Analysis
The protoplasts were washed twice in cold PBS and lysed with Laemmli sample buffer.
Proteins were separated by SDS-PAGE on 10% polyacrylamide gels and then transferred to
nitrocellulose. Membranes were blocked with 5% (w/v) non-fat dried milk in Tris-buffered
saline containing 0.1% (v/v) Tween 20 at room temperature for 1 h. After being blocked,
membranes were incubated overnight with primary antibodies, namely, anti-IDO1 (Merck
Millipore, Darmstadt, Germany), anti-GFP (Thermo Fisher Scientific, Waltham, MA, USA),
and anti-Rubisco large subunit (rbcL, Agrisera, Sweden), then washed and incubated with
appropriate horseradish peroxidase (HRP)-conjugated secondary antibody (Thermo Fisher
Scientific, Waltham, MA, USA) for 1 h at room temperature. Immunoreactive bands were
detected by enhanced chemiluminescence (Bio-Rad, Hercules, CA, USA).
4.8. Kynurenine Analysis
IDO1 functional activity was measured in protoplast culture supernatants in terms of
the ability to metabolise tryptophan to kynurenine, whose concentrations were measured
by using a Perkin Elmer, series 200 HPLC instrument (Waltham, MA, USA). A Kinetex®
C18 column (250× 4.6 µm, 5 µm, 100 Å; Phenomenex, USA), maintained at the temperature
of 37 ◦C and pressure of 1800 PSI, was used. Briefly, 1 × 106 transformed protoplasts were
resuspended in 1 mL of K3 medium alone or supplemented with exogenous L-tryptophan
100 µM (Sigma-Aldrich, St. Louis, MO, USA) which was added 2 h after transfection. Then,
following an incubation of 24 h at 25 ◦C in the dark, the K3 medium was recovered with a
Pasteur pipette and filtered with a syringe containing a cotton filter to eliminate remaining
protoplasts. After deproteinisation, the samples were eluted by a mobile phase containing
10 mM NaH2PO4 (pH = 3.0; 99%) and methanol (1%) (Sigma-Aldrich, St. Louis, MO, USA),
with a flow rate of 1.3 mL/min. A UV detector at 360 nm and 220 nm performed detection
of kynurenine and tryptophan, respectively. The software TURBOCHROM 4 was used for
evaluating the concentrations of kynurenine and tryptophan in the samples by mean of a
calibration curve.
4.9. Statistics
Data are representative of at least three independent experiments. All results are
shown as mean ± SD. One-way ANOVA followed by post hoc Bonferroni’s test was used
when three or more samples were under comparison. All analyses were performed using
Graph Pad Prism software 8.0.
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